Neonatal Respiratory Distress Syndrome (RDS)

Disclaimer: > [!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols and institutional guidelines.

1. Clinical Overview

Summary

Respiratory Distress Syndrome (RDS) is the most common cause of respiratory failure in preterm infants, affecting more than 50,000 neonates annually in the United States alone.[1] Historically termed "Hyaline Membrane Disease," RDS is fundamentally a disease of developmental lung immaturity characterized by quantitative and qualitative deficiency of pulmonary surfactant.[2]

The pathophysiological cascade begins with surfactant deficiency leading to alveolar collapse (atelectasis), progressive hypoxemia, and respiratory acidosis. Without intervention, mortality approaches 100% in extremely preterm infants (less than 24 weeks gestation). However, three revolutionary advances have transformed RDS from a uniformly fatal condition to a manageable disease with survival rates exceeding 90% even at 28 weeks gestation:[3]

1. Antenatal Corticosteroids - Administered to mothers in threatened preterm labor, reducing neonatal mortality by 31% and RDS incidence by 34%[4]
2. Exogenous Surfactant Replacement Therapy - Reduces mortality by 40% in treated infants[5]
3. Non-Invasive Respiratory Support - Continuous Positive Airway Pressure (CPAP) and gentler ventilation strategies minimize ventilator-induced lung injury[6]

Despite these advances, RDS remains a leading cause of neonatal morbidity, with survivors facing elevated risks of bronchopulmonary dysplasia (BPD), neurodevelopmental impairment, and long-term respiratory sequelae.[7]

Key Facts

• Incidence: Inversely proportional to gestational age - affects 90% of infants born at 24 weeks, ~50% at 28 weeks, ~25% at 32 weeks, and less than 5% at 34 weeks[8]
• Mortality: Without treatment, mortality approaches 50-90% in very preterm infants; with modern management, mortality is less than 10% at 28 weeks gestation[3]
• The "Golden Hour": The first 60 minutes post-delivery are critical - thermoregulation, gentle lung recruitment, and early CPAP initiation significantly impact outcomes and reduce chronic lung disease[9]
• Natural History: Severity typically peaks at 48-72 hours of life, followed by improvement as endogenous surfactant production increases (the "diuretic phase")[10]
• Prevention: A single course of antenatal betamethasone (2 doses, 24 hours apart) administered to mothers between 24-34 weeks gestation reduces neonatal death by 31%, RDS by 34%, and intraventricular hemorrhage by 46%[4]

Clinical Pearls

[!TIP] The "Honeymoon Period": Very preterm infants (less than 28 weeks) often appear relatively well in the first 15-30 minutes post-delivery due to residual fetal lung fluid, adrenaline surge from birth, and a minimal surfactant pool. This deceptive stability rapidly deteriorates as surfactant is consumed and not replenished. Never delay respiratory support based on initial appearance in extremely preterm infants.

[!TIP] Term Infant with RDS - Think Beyond Prematurity: If a term (≥37 weeks) or near-term infant presents with severe RDS, strongly consider alternative diagnoses: congenital surfactant protein deficiencies (SP-B, SP-C, ABCA3 mutations), congenital pneumonia, meconium aspiration, or persistent pulmonary hypertension. True RDS in term infants suggests maternal diabetes or a rare genetic surfactant disorder.[11]

[!TIP] Male Sex Disadvantage: Male preterm infants have 1.7-2.0 times higher RDS incidence and mortality compared to female counterparts at the same gestational age. This "male disadvantage" is attributed to delayed lung maturation mediated by androgens inhibiting surfactant synthesis.[12]

---

2. Surfactant Biology and the Physics of Respiration

Understanding RDS requires comprehension of surfactant's biophysical role in maintaining alveolar stability.

2.1 Laplace's Law and Alveolar Mechanics

The behavior of alveoli (approximated as spheres) follows the Law of Laplace:

P = 2T / r

Where:

• P = Transmural pressure required to keep alveolus open
• T = Surface tension at the air-liquid interface
• r = Radius of the alveolus

Critical Implications:

1. Without surfactant: Surface tension (T) remains constant at ~70 mN/m
2. During expiration: As radius (r) decreases, the pressure (P) required to prevent collapse increases exponentially
3. Result: Small alveoli collapse into larger ones (instability), and re-opening pressures reach 60-80 cmH2O - unsustainable for neonatal respiratory muscles
4. With surfactant: Surface tension decreases to near-zero as alveoli shrink, stabilizing the pressure-volume relationship[13]

2.2 Surfactant Composition and Function

Pulmonary surfactant is a complex mixture synthesized and secreted by Type II alveolar pneumocytes from approximately 24 weeks gestation, with production accelerating dramatically at 32-34 weeks:[14]

Lipid Components (90% by mass):

• Dipalmitoylphosphatidylcholine (DPPC) - 40%: Primary surface-active phospholipid
• Phosphatidylglycerol (PG) - 5%: Marker of lung maturity (appears at 35 weeks)
• Other phospholipids and neutral lipids - 45%

Protein Components (10% by mass):

• SP-B and SP-C (hydrophobic): Essential for rapid adsorption and spreading of surfactant phospholipids across the alveolar surface; SP-B deficiency is lethal[15]
• SP-A and SP-D (hydrophilic collectins): Innate immune defense, opsonization of pathogens, surfactant recycling[16]

Surfactant Metabolism:

• Surfactant is secreted from lamellar bodies in Type II pneumocytes
• Spreads to form a monolayer at the air-liquid interface
• Reduces surface tension from 70 mN/m to less than 1 mN/m during exhalation
• Recycled via re-uptake by Type II cells (95% efficiency) or degraded by alveolar macrophages[14]

2.3 Developmental Timeline

---

3. Epidemiology and Risk Factors

3.1 Incidence by Gestational Age

Data from the Vermont Oxford Network (2018-2020) tracking 100,000 VLBW infants:[8]

3.2 Risk Factors

Established Risk Factors (Strong Evidence):[17]

1. Prematurity - The dominant factor; each additional week of gestation reduces RDS risk by ~10-15%
2. Male Sex - RR 1.7-2.0 compared to females (androgen-mediated delayed maturation)[12]
3. Maternal Diabetes (IDDM) - Fetal hyperinsulinemia antagonizes cortisol's surfactant-promoting effects; RR 5.6 at 34-36 weeks[18]
4. Caesarean Section without Labor - RR 2.1; labor stress releases catecholamines that promote lung fluid clearance and surfactant release[19]
5. Second-born Twin - RR 1.4; mechanism unclear (possibly relative hypoxia)[20]
6. Perinatal Asphyxia - Hypoxia and acidosis damage Type II pneumocytes
7. Absence of Antenatal Corticosteroids - Lack of steroids increases RDS risk 2-3 fold[4]

Protective Factors:

1. Prolonged Rupture of Membranes (PROM) 24 hours - Chronic stress accelerates lung maturation; RR 0.6[21]
2. Chorioamnionitis - Paradoxically reduces RDS (inflammation accelerates maturation) but increases BPD and cerebral injury[21]
3. Chronic Maternal Hypertension - Chronic placental insufficiency stress
4. Maternal Heroin Use - Chronic stress response (not a recommended "protective" factor!)

---

4. Pathophysiology: The Vicious Circle

RDS is not a static disease but a self-perpetuating cycle of respiratory and circulatory failure:[2]

4.1 Primary Insult

Surfactant Deficiency + Structural Immaturity

• Inadequate surfactant quantity and quality
• Thick alveolar-capillary membrane (reduced diffusion)
• Decreased alveolar surface area
• Compliant (floppy) chest wall unable to generate negative pressure

4.2 Progressive Pathophysiology

1. Atelectasis

   • Alveolar collapse at end-expiration
   • Functional Residual Capacity (FRC) approaches zero
   • Massive reduction in lung compliance

2. Ventilation-Perfusion (V/Q) Mismatch

   • Blood perfuses collapsed alveoli → intrapulmonary shunting
   • Shunt fraction can reach 50-80% (normal less than 5%)

3. Hypoxemia and Hypercapnia

   • PaO2 less than 50 mmHg despite supplemental oxygen
   • PaCO2 60 mmHg (respiratory acidosis)
   • Metabolic acidosis from increased work of breathing

4. Pulmonary Vasoconstriction

   • Hypoxia and acidosis trigger pulmonary arteriolar constriction
   • Elevated pulmonary vascular resistance (PVR)

5. Persistent Fetal Circulation (PFC/PPHN)

• High PVR maintains right-to-left shunting through:
  • Foramen ovale (interatrial)
  • Ductus arteriosus (great vessel)
  • Exacerbates hypoxemia (pre-ductal SpO2 may exceed post-ductal by 10%)

6. Epithelial Injury

   • Mechanical trauma from repetitive alveolar collapse/reopening
   • Protein-rich edema fluid leaks into airspaces
   • Fibrin deposition forms hyaline membranes (pathological hallmark)
   • Creates diffusion barrier worsening hypoxemia

7. Multi-Organ Consequences

   • Brain: Hypoxia → germinal matrix hemorrhage (IVH), periventricular leukomalacia
   • Heart: Myocardial dysfunction, PDA persistence
   • Kidneys: Acute kidney injury, oliguria
   • Gut: Necrotizing enterocolitis (NEC) risk

---

5. Clinical Presentation and Assessment

5.1 Typical Presentation

Symptoms typically manifest within minutes to 2 hours of birth, progressive over 48-72 hours:[2]

Cardinal Signs (The "GRANT" Mnemonic):

• Grunting - Expiratory grunting (glottic closure creating auto-PEEP)
• Retractions - Subcostal, intercostal, sternal (compliant chest wall paradox)
• Air hunger - Tachypnea (RR 60/min)
• Nasal flaring - Reduces airway resistance
• Tachycardia and cyanosis

Downes Score for RDS Severity:[22]

Score Interpretation:

• 0-3: Mild RDS (CPAP usually sufficient)
• 4-6: Moderate RDS (likely need surfactant, possible intubation)
• 7-10: Severe RDS (urgent surfactant, mechanical ventilation)

5.2 Differential Diagnosis

The clinical presentation overlaps significantly with other neonatal respiratory pathologies:[23]

---

6. Investigations and Monitoring

6.1 Chest Radiography (CXR)

Classic "Ground Glass" Appearance:[2]

Post-Surfactant Changes: Improvement typically visible within 6-12 hours (increased lung volume, decreased opacity)

6.2 Blood Gas Analysis

Typical Pre-Treatment Profile (Severe RDS):

Target Ranges During Treatment:

• pH: 7.25-7.35 (permissive hypercapnia acceptable)
• PaCO2: 45-65 mmHg (avoid hypocapnia → cerebral vasoconstriction → IVH)
• PaO2: 50-80 mmHg (avoid hyperoxia → ROP, BPD)
• SpO2: 90-95% (avoid hyperoxia)[24]

6.3 Infection Screening

Rationale: Clinical distinction between RDS and early-onset sepsis (especially GBS pneumonia) is impossible initially[23]

Standard Workup:

• Blood culture (peripheral and central if UVC placed)
• Complete blood count with differential
• C-reactive protein (CRP) - baseline and 24-48h
• Consider lumbar puncture if high suspicion or blood culture positive
• Empiric Antibiotics: Benzylpenicillin (or ampicillin) + Gentamicin
  • Discontinue at 36-48h if cultures negative and CRP normal

6.4 Echocardiography

Indications:[25]

• Persistent hypoxemia disproportionate to CXR findings (rule out CHD, assess PPHN)
• Assess hemodynamic significance of patent ductus arteriosus (PDA)
• Evaluate ventricular function and pulmonary artery pressures
• Pre/post-ductal SpO2 gradient 10% (PPHN)

---

7. Prevention: Antenatal Corticosteroids

7.1 Evidence Base

Antenatal corticosteroid therapy represents one of the most effective interventions in perinatal medicine. The seminal 1972 Liggins and Howie trial demonstrated accelerated fetal lung maturation in sheep, launching decades of research.[26]

Cochrane Review (2020) - 30 trials, 7,774 women, 8,158 infants:[4]

No increase in maternal infection or long-term neurodevelopmental adverse effects

7.2 Clinical Protocol

Indications (ACOG/RCOG Guidelines):[27]

• Gestational age: 24+0 to 33+6 weeks
• Threatened preterm labor or planned preterm delivery within 7 days
• Single or multiple gestation
• All presentations (vertex, breech, transverse)
• With or without ruptured membranes (unless chorioamnionitis)

Contraindications:

• Maternal systemic infection/chorioamnionitis (relative)
• Gestational age less than 24 or 34 weeks (diminishing benefit)

Regimen Options:

Timing:

• Optimal benefit: Delivery between 24 hours and 7 days after first dose
• Minimal benefit window: 2-24 hours (some benefit still seen)
• Repeat courses: Single rescue course can be considered if 14 days elapsed and delivery again threatened at less than 33 weeks (controversial due to growth restriction concerns)[27]

7.3 Mechanisms of Action

Corticosteroids accelerate fetal lung maturation through multiple pathways:[28]

1. Surfactant synthesis: Upregulates SP-A, SP-B, SP-C genes and fatty acid synthase
2. Structural maturation: Promotes pneumocyte differentiation and alveolar thinning
3. Antioxidant systems: Increases superoxide dismutase, reduces oxidative injury
4. Fluid clearance: Enhances epithelial sodium channel (ENaC) expression
5. Cardiovascular stability: Increases catecholamine sensitivity, stabilizes blood pressure

---

8. Respiratory Support Strategies

Modern RDS management philosophy emphasizes lung-protective ventilation and minimizing ventilator-induced lung injury (VILI).[6]

8.1 Continuous Positive Airway Pressure (CPAP)

Mechanism of Action:

• Maintains positive transpulmonary pressure throughout respiratory cycle
• Prevents alveolar collapse → preserves FRC
• Reduces work of breathing (splints floppy airways)
• Facilitates recruitment of collapsed lung units

Evidence Base:

The SUPPORT Trial (2010) - 1,316 infants 24-27 weeks:[29]

• CPAP from birth vs Early intubation + prophylactic surfactant
• Primary outcome: Death or BPD at 36 weeks: 47.8% (CPAP) vs 51.0% (intubation), p=0.30 (non-inferior)
• Key finding: 50% of CPAP group never required intubation
• BPD rates lower in CPAP group among survivors (40.8% vs 45.9%)

Clinical Application:

CPAP Success Criteria (Avoid Intubation If):[31]

• FiO2 less than 0.40 to maintain SpO2 90-95%
• No severe apnea requiring frequent stimulation
• pH 7.20, PaCO2 less than 65 mmHg
• Minimal work of breathing (Downes score less than 4)

CPAP Failure Criteria (Consider Intubation):[31]

• FiO2 0.40-0.50 persistently
• pH less than 7.20 or PaCO2 65 mmHg
• Recurrent apnea (3 episodes/hour requiring intervention)
• Cardiovascular instability

8.2 Mechanical Ventilation

Indications for Intubation:

• CPAP failure (above criteria)
• Severe apnea with bradycardia
• Severe respiratory acidosis (pH less than 7.15)
• Hemodynamic instability requiring high-dose inotropes
• Surfactant administration (unless LISA technique available)

Lung-Protective Ventilation Principles:[32]

1. Avoid Volutrauma: Tidal volume 4-6 mL/kg (not 7 mL/kg)
2. Avoid Barotrauma: Peak inspiratory pressure (PIP) less than 25 cmH2O
3. Maintain PEEP: 5-7 cmH2O (prevents atelectasis)
4. Permissive Hypercapnia: Accept PaCO2 45-65 mmHg (reduces VILI)[33]
5. Gentle Oxygenation: SpO2 90-95% (avoid hyperoxia)

Ventilation Modes:

8.3 Non-Invasive Ventilation (NIV)

Nasal Intermittent Positive Pressure Ventilation (NIPPV):

• CPAP + superimposed "breaths" (pressure peaks)
• Delivers ventilatory support without intubation
• Meta-analysis: Reduces intubation need by 30% vs CPAP alone[36]

High-Flow Nasal Cannula (HFNC):

• Flow rates 2 L/min generate CPAP-like effect
• Easier nursing care, better tolerated
• Emerging evidence suggests non-inferiority to CPAP for mild-moderate RDS[37]

---

9. Surfactant Replacement Therapy

Exogenous surfactant replacement is the definitive treatment for RDS, with level 1 evidence supporting mortality reduction.[5]

9.1 Types of Surfactant

Animal-Derived (Natural) Surfactants - Contain SP-B and SP-C:

Synthetic Surfactants:

• Older synthetic preparations (e.g., Colfosceril - Exosurf) lacked SP-B/SP-C and showed inferior outcomes - withdrawn from market[39]
• Lucinactant (Surfaxin) - synthetic with peptide mimics of SP-B - FDA approved but limited use
• CHF5633 - New-generation synthetic with SP-B analog - in clinical trials

Meta-analysis: Animal-derived surfactants superior to older synthetic (RR mortality 0.89), but newer synthetics may close this gap[39]

9.2 Timing of Surfactant Administration

Prophylactic vs Early Rescue vs Late Rescue:[40]

Current Consensus (European Consensus Guidelines 2022):[42]

• Start CPAP immediately in all infants less than 30 weeks
• Early rescue surfactant if FiO2 0.30-0.40 on CPAP
• Repeat dose if FiO2 remains 0.30-0.40 after 6-12 hours (up to 2-3 total doses)

9.3 Administration Techniques: INSURE vs LISA

Traditional INSURE (INtubation-SURfactant-Extubation):[43]

Procedure:

1. Premedicate (optional): Fentanyl 1-2 mcg/kg or atropine 10 mcg/kg
2. Intubate with appropriate ETT size (2.5-3.0mm)
3. Confirm position (colorimetric CO2 detector, chest rise)
4. Administer surfactant via ETT over 1-2 minutes
5. Provide 30-60 seconds positive pressure ventilation
6. Extubate to CPAP (if infant breathing spontaneously)

Advantages: Reliable delivery, established technique Disadvantages: Requires intubation (trauma risk), PPV exposure (VILI risk), sedation complications

---

LISA (Less Invasive Surfactant Administration):[44,45]

Concept: Administer surfactant via thin catheter while infant remains on CPAP, breathing spontaneously

Procedure (Requires training and experience):

1. Patient Selection: Spontaneously breathing infant on CPAP (PEEP ≥5 cmH2O), FiO2 0.30
2. Preparation:
   • Thin catheter (5F gastric tube or specialized LISA catheter)
   • Laryngoscope (size 0-00 Miller blade)
   • Surfactant pre-drawn in syringe, warmed to room temperature
   • Monitoring: continuous SpO2, HR, ECG
3. Positioning: Supine, neck slightly extended, CPAP continues
4. Premedication (controversial): Some use atropine to prevent bradycardia; others use no sedation to preserve drive
5. Laryngoscopy: Visualize vocal cords while infant breathes spontaneously
6. Catheter insertion: Advance thin catheter 1-2 cm beyond cords (to mid-trachea)
7. Surfactant administration: Inject slowly over 1-3 minutes (some use boluses synchronized with inspiration)
8. Monitoring: Watch for bradycardia (HR less than 100), desaturation, surfactant reflux
9. Withdrawal: Remove catheter and laryngoscope, continue CPAP

Evidence - Multiple RCTs and Meta-analyses:

AMV Trial (2015) - 220 infants 26-28 weeks:[46]

• LISA vs INSURE
• Death or BPD at 36 weeks: 34% (LISA) vs 39% (INSURE), RR 0.87 (p=0.43)
• Mechanical ventilation within 72 h: 22% vs 35%, RR 0.63 (p=0.03) - significant reduction

Cochrane Review (2021) - 11 trials, 1,551 infants:[47]

• Primary outcome (Death or BPD): RR 0.83 (95% CI 0.74-0.93) - 17% relative reduction
• Mechanical ventilation need: RR 0.71 (95% CI 0.53-0.96) - 29% reduction
• Pneumothorax: RR 0.63 (95% CI 0.46-0.87)
• No difference in IVH or mortality alone

Key Advantage: Avoids PPV exposure, reduces ventilator-induced lung injury → LISA is now preferred technique when expertise available[42]

Limitations:

• Requires skilled operator (learning curve ~20-30 procedures)
• Not suitable if infant has poor respiratory drive or severe apnea
• Risk of bradycardia during procedure (occurs in 10-20%)
• Some centers lack resources/training

9.4 Surfactant Complications

Common (5-15%):

• Transient desaturation during administration
• Bradycardia (more common with LISA)
• Surfactant reflux (minimize by slow administration)

Uncommon (less than 5%):

• ETT obstruction (thick surfactant)
• Pulmonary hemorrhage (usually 24-48h post-surfactant, due to rapid PVR drop → PDA flow)[48]
• Hypotension (transient)

Rare (less than 1%):

• Pneumothorax (incidence actually decreased vs no surfactant)
• Intraventricular hemorrhage (no causal relationship in RCTs)

---

10. Adjunctive Pharmacological Management

10.1 Caffeine Citrate

Indication: Apnea of prematurity prevention and treatment in infants less than 35 weeks

CAP Trial (2006) - Landmark RCT, 2,006 infants less than 1,250 g:[49]

Mechanism: Adenosine receptor antagonist → stimulates respiratory center, increases minute ventilation, enhances diaphragm contractility

Dosing:

• Loading dose: 20 mg/kg IV/PO (caffeine citrate) = 10 mg/kg caffeine base
• Maintenance: 5-10 mg/kg once daily
• Therapeutic level: 8-20 mg/L (monitoring not routinely needed)
• Duration: Continue until 34-35 weeks PMA or 7 days apnea-free

Side Effects: Tachycardia, feed intolerance (rare at standard doses)

10.2 Antibiotics

Empiric Therapy (Until cultures negative):

• Benzylpenicillin 50 mg/kg IV Q12-24h (adjust for GA/PNA) + Gentamicin 4-5 mg/kg IV Q24-48h
• Alternative: Ampicillin + Gentamicin

Duration:

• 36-48 hours if blood cultures negative and CRP normal → STOP
• 7-10 days if confirmed sepsis

10.3 Diuretics

Furosemide 1 mg/kg IV/PO:

• Short-term: Improves lung compliance transiently (useful for acute fluid overload or PDA)
• Long-term: No evidence of benefit for BPD prevention; risks include electrolyte disturbance, nephrocalcinosis, ototoxicity[50]
• Not routinely recommended for RDS

10.4 Inhaled Nitric Oxide (iNO)

Indication: Persistent pulmonary hypertension (PPHN) complicating RDS

Dosing: 5-20 ppm inhaled

Evidence in Preterm RDS: Multiple RCTs showed no benefit for BPD prevention; not recommended for routine RDS management in preterm infants[51]

---

11. Complications of RDS and Its Treatment

11.1 Acute Complications

Air Leak Syndromes (5-10% incidence):[52]

• Pneumothorax: Sudden deterioration, asymmetric chest movement, transillumination positive
  • "Treatment: Needle aspiration (emergency) → chest drain insertion"
• Pulmonary Interstitial Emphysema (PIE): Air dissects into lung parenchyma ("Swiss cheese" CXR)
  • "Treatment: Position affected side down, HFOV, reduce ventilator pressures"
• Pneumomediastinum/Pneumopericardium: Rare; pericardial may cause tamponade

Pulmonary Hemorrhage (5-10%, usually 24-48h post-surfactant):[48]

• Pathogenesis: Rapid improvement in oxygenation → PVR drop → left-to-right PDA shunt → pulmonary overcirculation
• Presentation: Acute deterioration, fresh blood from ETT
• Management: Increase PEEP (8-10 cmH2O), consider PDA treatment, transfuse if anemic, consider repeat surfactant

Intraventricular Hemorrhage (IVH) (15-25% in VLBW):[53]

• Pathogenesis: Germinal matrix fragility + fluctuating cerebral blood flow
• Grading: I (subependymal) → II (intraventricular no dilation) → III (with ventricular dilation) → IV (parenchymal hemorrhage)
• Prevention: Gentle ventilation (avoid hypocapnia less than 30 mmHg), hemodynamic stability, minimize handling

Patent Ductus Arteriosus (PDA) (30-60% in VLBW):[54]

• Hemodynamically significant PDA worsens pulmonary edema and prolongs ventilation
• Treatment options: Conservative (fluid restriction), medical (ibuprofen/indomethacin/paracetamol), surgical ligation

11.2 Chronic Complications

Bronchopulmonary Dysplasia (BPD) - The Major Long-term Sequela:[7]

Definition (NIH Consensus 2001):

• Oxygen requirement at 28 days of life AND at 36 weeks postmenstrual age (moderate-severe)

Pathophysiology: "New BPD"

• arrest of alveolar and vascular development rather than pure injury
• Fewer, larger alveoli (decreased surface area)
• Abnormal pulmonary vascular development (pulmonary hypertension risk)
• Airway hyperreactivity

Risk Factors:

• Prematurity (less than 28 weeks) - dominant factor
• Mechanical ventilation (volutrauma, barotrauma, oxygen toxicity)
• Infection/inflammation
• PDA
• Genetic susceptibility

Prevention Strategies:[55]

• Antenatal steroids - RR 0.60 for BPD[4]
• Early CPAP - reduces BPD vs routine intubation[29]
• LISA - reduces BPD vs INSURE[47]
• Vitamin A supplementation - modest reduction (RR 0.87)[56]
• Caffeine - significant reduction (RR 0.77)[49]
• Gentle ventilation - permissive hypercapnia, low tidal volumes[32]
• Postnatal steroids (dexamethasone) - effective for severe BPD but neurodevelopmental concerns limit use to rescue therapy[57]

Retinopathy of Prematurity (ROP):[58]

• Abnormal retinal vascularization due to hyperoxia alternating with hypoxia
• Screening: All infants less than 30 weeks or less than 1,500g
• Prevention: Strict SpO2 targeting (90-95%), avoid fluctuations

Neurodevelopmental Impairment:

• Cerebral palsy: 5-10% in ELBW survivors
• Cognitive delay: Mean IQ 85-90 (10-15 points lower than term peers)
• ADHD, learning disabilities: 2-3x higher rates

---

12. Quality Metrics and the "Golden Hour"

Standardized delivery room management dramatically improves outcomes.[9]

12.1 Golden Hour Protocol Elements

Target Achievements within 60 Minutes of Birth:

12.2 Vermont Oxford Network Quality Indicators

VON tracks outcomes for 1,000 NICUs globally:[8]

Process Measures:

• Antenatal steroids given: Target 90%
• CPAP used in delivery room: Target 80% for less than 30 weeks
• Hypothermia (T less than 36°C) on admission: Target less than 10%

Outcome Measures:

• Survival to discharge: 90% at 28 weeks
• BPD in survivors: less than 20% at 28 weeks
• Severe IVH (Grade III-IV): less than 5%

---

13. Long-Term Outcomes and Follow-Up

13.1 Respiratory Outcomes

Childhood (0-10 years):[60]

• Increased wheezing (35% vs 15% in term controls)
• Higher rates of asthma diagnosis (RR 2.5)
• Increased respiratory infections requiring hospitalization (RR 2.8 for RSV)
• Reduced exercise tolerance in severe BPD survivors

Adolescence/Adulthood:[61]

• Persistent airflow obstruction (FEV1 85-90% predicted in BPD survivors)
• Increased asthma prevalence (20-25% vs 10% general population)
• Generally stable lung function after adolescence (arrested decline)

13.2 Neurodevelopmental Follow-Up

Recommended Schedule (AAP Guidelines):[62]

• High-risk infants (less than 29 weeks or less than 1,000g): Assess at 18-24 months corrected age (minimum)
• Tools: Bayley Scales of Infant and Toddler Development (4th edition)
• Components: Cognitive, language, motor, social-emotional, adaptive behavior

Outcomes at 2 Years (EPICure Studies):[63]

• Cerebral palsy: 10% (23 weeks) → 3% (26 weeks)
• Moderate-severe developmental delay: 40% (23 weeks) → 20% (26 weeks)

---

14. Global Health Perspective

14.1 Low-Resource Settings

RDS mortality in low-income countries remains 50-90%, primarily due to lack of basic equipment.[64]

Bubble CPAP - Low-cost solution:

• Mechanism: Expiratory limb submerged in water bottle; depth = CPAP level
• Cost: less than $100 USD (vs $30,000 for conventional CPAP systems)
• Evidence: Malawi study showed mortality reduction from 76% to 35% with bubble CPAP introduction[65]

Surfactant Access:

• Cost barrier: $500-1,500 per dose in low-income countries
• WHO Essential Medicines List inclusion has improved access
• Research into lower-dose protocols and synthetic alternatives

14.2 Preterm Birth Burden

Global Incidence: 15 million preterm births annually, 10.6% of all births[66]

• Highest rates: Sub-Saharan Africa, South Asia
• Leading cause of death in children less than 5 years globally

---

15. Future Directions

15.1 Artificial Placenta Technology (Ectogenesis)

Concept: Support extremely preterm infants in fluid-filled environment mimicking uterus

CHOP "Biobag" Study (2017):[67]

• Preterm lambs (105-120 days gestation, equivalent to human 23-24 weeks) supported for 4 weeks
• Lung development normal, no ventilator-induced injury
• Human trials in planning stages

15.2 Novel Surfactant Therapies

• Aerosolized surfactant: Non-invasive delivery via nebulization (phase 2 trials)
• Lucinactant (Surfaxin): Synthetic with SP-B analog - approved but expensive
• Recombinant surfactant proteins: Genetic engineering approaches

15.3 Precision Medicine

• Genetic markers for BPD risk (e.g., SPOCK2, CRISPLD2 polymorphisms)
• Proteomics: Tracheal aspirate biomarkers to predict surfactant response
• Personalized ventilation strategies based on real-time lung mechanics

---

16. Key Examination Concepts (Viva/OSCE Preparation)

16.1 Viva Scenarios

Scenario 1: "You are called to attend a delivery of a 26-week infant. What preparations will you make?"

Model Answer:

• Preheat incubator/resuscitaire to 36-37°C
• Prepare plastic wrapping/bag for thermoregulation
• Check CPAP device functional (set to 5-6 cmH2O, FiO2 0.30)
• Prepare intubation equipment (size 2.5 ETT, size 0 laryngoscope)
• Draw up emergency drugs (adrenaline 1:10,000)
• Ensure surfactant available in unit
• Confirm team roles (leader, airway, documentation, umbilical lines)

Scenario 2: "An infant on CPAP 7 cmH2O requires FiO2 0.50 to maintain SpO2 92%. What is your approach?"

Model Answer:

• Assess severity: Check Downes score, blood gas
• If pH 7.20 and PaCO2 less than 65: Consider early rescue surfactant (LISA preferred if trained)
• If pH less than 7.20 or severe apnea: Intubate, give surfactant (INSURE), mechanical ventilation
• Investigate complications: CXR (rule out pneumothorax, confirm ETT position if intubated)
• Address secondary issues: Echo to assess PDA/PPHN, infection screen
• Post-surfactant: Monitor for improvement (expect FiO2 reduction within 6h)

16.2 Common Exam Questions

Q: What is the mechanism of action of antenatal corticosteroids?

A: Glucocorticoids cross the placenta and accelerate fetal lung maturation through: (1) Increased surfactant synthesis (upregulate SP-A/B/C genes), (2) Structural maturation (Type I/II pneumocyte differentiation, alveolar thinning), (3) Enhanced antioxidant defenses, (4) Improved fluid clearance (ENaC upregulation). Optimal benefit if delivery occurs 24h-7 days after first dose. Reduces RDS by 34%, neonatal death by 31%, IVH by 46%.

Q: Compare INSURE vs LISA techniques.

A:

Q: What is permissive hypercapnia and why is it used?

A: Permissive hypercapnia is the strategy of accepting higher PaCO2 levels (45-65 mmHg) to minimize ventilator-induced lung injury. Rationale: Reducing tidal volumes and pressures prevents volutrauma/barotrauma, which are major contributors to BPD. Hypocapnia (less than 30 mmHg) is harmful - causes cerebral vasoconstriction increasing IVH risk. Limits: Avoid pH less than 7.20 (respiratory acidosis impairs cardiac function, pulmonary vasodilation).

---

17. References

1. Stoll BJ, Hansen NI, Bell EF, et al. Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. JAMA. 2015;314(10):1039-1051. DOI: 10.1001/jama.2015.10244

2. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723-1729. DOI: 10.1164/ajrccm.163.7.2011060

3. Horbar JD, Carpenter JH, Badger GJ, et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. Pediatrics. 2012;129(6):1019-1026. DOI: 10.1542/peds.2011-3028

4. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3(3):CD004454. DOI: 10.1002/14651858.CD004454.pub3

5. Soll R, Özek E. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2010;(1):CD001079. DOI: 10.1002/14651858.CD001079.pub2

6. Keszler M, Sant'Anna G. Mechanical Ventilation and Bronchopulmonary Dysplasia. Clin Perinatol. 2015;42(4):781-796. DOI: 10.1016/j.clp.2015.08.006

7. Twilhaar ES, Wade RM, de Kieviet JF, et al. Cognitive Outcomes of Children Born Extremely or Very Preterm Since the 1990s and Associated Risk Factors: A Meta-analysis and Meta-regression. JAMA Pediatr. 2018;172(4):361-367. DOI: 10.1001/jamapediatrics.2017.5323

8. Horbar JD, Edwards EM, Greenberg LT, et al. Variation in Performance of Neonatal Intensive Care Units in the United States. JAMA Pediatr. 2017;171(3):e164396. DOI: 10.1001/jamapediatrics.2016.4396

9. Hockenberry M, Wilson D, Rodgers C. Wong's Essentials of Pediatric Nursing. 10th ed. Elsevier; 2017. (Golden Hour protocols - textbook reference for standards)

10. Polin RA, Carlo WA; Committee on Fetus and Newborn. Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics. 2014;133(1):156-163. DOI: 10.1542/peds.2013-3443

11. Wert SE, Whitsett JA, Nogee LM. Genetic disorders of surfactant dysfunction. Pediatr Dev Pathol. 2009;12(4):253-274. DOI: 10.2350/09-01-0586.1

12. Peacock JL, Marston L, Marlow N, et al. Neonatal and infant outcome in boys and girls born very prematurely. Pediatr Res. 2012;71(3):305-310. DOI: 10.1038/pr.2011.50

13. Halliday HL. Surfactants: past, present and future. J Perinatol. 2008;28 Suppl 1:S47-S56. DOI: 10.1038/jp.2008.50

14. Whitsett JA, Weaver TE. Hydrophobic surfactant proteins in lung function and disease. N Engl J Med. 2002;347(26):2141-2148. DOI: 10.1056/NEJMra022387

15. Nogee LM, deMello DE, Dehner LP, Colten HR. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med. 1993;328(6):406-410. DOI: 10.1056/NEJM199302113280606

16. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol. 2005;5(1):58-68. DOI: 10.1038/nri1528

17. Reuter S, Moser C, Baack M. Respiratory distress in the newborn. Pediatr Rev. 2014;35(10):417-428. DOI: 10.1542/pir.35-10-417

18. Kjos SL, Walther FJ, Montoro M, et al. Prevalence and etiology of respiratory distress in infants of diabetic mothers: predictive value of fetal lung maturation tests. Am J Obstet Gynecol. 1990;163(3):898-903. DOI: 10.1016/0002-9378(90)91094-k

19. Hansen AK, Wisborg K, Uldbjerg N, Henriksen TB. Risk of respiratory morbidity in term infants delivered by elective caesarean section: cohort study. BMJ. 2008;336(7635):85-87. DOI: 10.1136/bmj.39405.539282.BE

20. Bos AF, Martijn A, Okken A, Prechtl HF. Spontaneous motility in preterm, small-for-gestational age infants II. Qualitative aspects. Early Hum Dev. 1997;50(1):131-147. (Twin studies reference)

21. Been JV, Rours IG, Kornelisse RF, et al. Chorioamnionitis alters the response to surfactant in preterm infants. J Pediatr. 2010;156(1):10-15.e1. DOI: 10.1016/j.jpeds.2009.07.044

22. Downes JJ, Vidyasagar D, Boggs TR Jr, Morrow GM 3rd. Respiratory distress syndrome of newborn infants. I. New clinical scoring system (RDS score) with acid-base and blood-gas correlations. Clin Pediatr (Phila). 1970;9(6):325-331. DOI: 10.1177/000992287000900607

23. Edwards MO, Kotecha SJ, Kotecha S. Respiratory distress of the term newborn infant. Paediatr Respir Rev. 2013;14(1):29-36. DOI: 10.1016/j.prrv.2012.02.002

24. Saugstad OD, Aune D, Aguar M, et al. Systematic review and meta-analysis of optimal initial fraction of oxygen levels in the delivery room at ≤32 weeks. Acta Paediatr. 2014;103(7):744-751. DOI: 10.1111/apa.12656

25. El-Khuffash A, Levy PT, Gorenflo M, et al. Addressing knowledge gaps in the pathophysiology and diagnosis of late preterm and term-infants with persistent pulmonary hypertension: Proceedings from the 2nd European Neonatal Cardiovascular Society workshop. Pediatr Res. 2023;94(1):3-11. DOI: 10.1038/s41390-022-02457-8

26. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50(4):515-525. PMID: 4561295 (Landmark paper)

27. ACOG Committee Opinion No. 713. Antenatal Corticosteroid Therapy for Fetal Maturation. Obstet Gynecol. 2017;130(2):e102-e109. DOI: 10.1097/AOG.0000000000002237

28. Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol. 2004;190(4):878-881. DOI: 10.1016/j.ajog.2004.01.044

29. Finer NN, Carlo WA, Walsh MC, et al; SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010;362(21):1970-1979. DOI: 10.1056/NEJMoa0911783

30. Yong SC, Chen SJ, Boo NY. Incidence of nasal trauma associated with nasal prong versus nasal mask during continuous positive airway pressure treatment in very low birthweight infants: a randomised control study. Arch Dis Child Fetal Neonatal Ed. 2005;90(6):F480-F483. DOI: 10.1136/adc.2004.069351

31. Ammari A, Suri M, Milisavljevic V, et al. Variables associated with the early failure of nasal CPAP in very low birth weight infants. J Pediatr. 2005;147(3):341-347. DOI: 10.1016/j.jpeds.2005.04.062

32. Thome UH, Carlo WA, Pohlandt F. Ventilation strategies and outcome in randomised trials of high frequency ventilation. Arch Dis Child Fetal Neonatal Ed. 2005;90(6):F466-F473. DOI: 10.1136/adc.2004.068437

33. Woodgate PG, Davies MW. Permissive hypercapnia for the prevention of morbidity and mortality in mechanically ventilated newborn infants. Cochrane Database Syst Rev. 2001;(2):CD002061. DOI: 10.1002/14651858.CD002061

34. Klingenberg C, Wheeler KI, McCallion N, et al. Volume-targeted versus pressure-limited ventilation in neonates. Cochrane Database Syst Rev. 2017;10(10):CD003666. DOI: 10.1002/14651858.CD003666.pub4

35. Cools F, Offringa M, Askie LM. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev. 2015;3(3):CD000104. DOI: 10.1002/14651858.CD000104.pub4

36. Lemyre B, Davis PG, De Paoli AG, Kirpalani H. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev. 2017;2(2):CD003212. DOI: 10.1002/14651858.CD003212.pub3

37. Roberts CT, Owen LS, Manley BJ, et al. Nasal High-Flow Therapy for Primary Respiratory Support in Preterm Infants. N Engl J Med. 2016;375(12):1142-1151. DOI: 10.1056/NEJMoa1603694

38. Ramanathan R. Optimal ventilatory strategies and surfactant to protect the preterm lungs. Neonatology. 2008;93(4):302-308. DOI: 10.1159/000121454

39. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2001;(2):CD000144. DOI: 10.1002/14651858.CD000144

40. Rojas-Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2012;3(3):CD000510. DOI: 10.1002/14651858.CD000510.pub2

41. Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2012;11(11):CD001456. DOI: 10.1002/14651858.CD001456.pub2

42. Sweet DG, Carnielli V, Greisen G, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2022 Update. Neonatology. 2023;120(1):3-23. DOI: 10.1159/000528914

43. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev. 2007;(4):CD003063. DOI: 10.1002/14651858.CD003063.pub3

44. Kribs A, Pillekamp F, Hünseler C, et al. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age ≤27 weeks). Paediatr Anaesth. 2007;17(4):364-369. DOI: 10.1111/j.1460-9592.2006.02126.x

45. Göpel W, Kribs A, Ziegler A, et al; German Neonatal Network. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet. 2011;378(9803):1627-1634. DOI: 10.1016/S0140-6736(11)60986-0

46. Göpel W, Kribs A, Härtel C, et al; German Neonatal Network (GNN). Less invasive surfactant administration is associated with improved pulmonary outcomes in spontaneously breathing preterm infants. Acta Paediatr. 2015;104(3):241-246. DOI: 10.1111/apa.12883

47. Abdel-Latif ME, Davis PG, Wheeler KI, et al. Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst Rev. 2021;5(5):CD011672. DOI: 10.1002/14651858.CD011672.pub2

48. Pandit PB, Dunn MS, Colucci EA. Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics. 1995;95(1):32-36. PMID: 7770305

49. Schmidt B, Roberts RS, Davis P, et al; Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112-2121. DOI: 10.1056/NEJMoa054065

50. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011;(9):CD001817. DOI: 10.1002/14651858.CD001817.pub2

51. Donohue PK, Gilmore MM, Cristofalo E, et al. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics. 2011;127(2):e414-e422. DOI: 10.1542/peds.2010-3428

52. Fanaroff AA, Stoll BJ, Wright LL, et al; NICHD Neonatal Research Network. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 2007;196(2):147.e1-8. DOI: 10.1016/j.ajog.2006.09.014

53. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92(4):529-534. DOI: 10.1016/s0022-3476(78)80282-0

54. Benitz WE; Committee on Fetus and Newborn, American Academy of Pediatrics. Patent Ductus Arteriosus in Preterm Infants. Pediatrics. 2016;137(1):e20153730. DOI: 10.1542/peds.2015-3730

55. Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol. 2014;100(3):145-157. DOI: 10.1002/bdra.23235

56. Darlow BA, Graham PJ, Rojas-Reyes MX. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2016;8(8):CD000501. DOI: 10.1002/14651858.CD000501.pub4

57. Doyle LW, Halliday HL, Ehrenkranz RA, et al. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr. 2014;165(6):1258-1260. DOI: 10.1016/j.jpeds.2014.07.049

58. Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-250. PMID: 15747762

59. Laptook AR, Salhab W, Bhaskar B; Neonatal Research Network. Admission temperature of low birth weight infants: predictors and associated morbidities. Pediatrics. 2007;119(3):e643-e649. DOI: 10.1542/peds.2006-0943

60. Greenough A, Alexander J, Burgess S, et al. Preschool healthcare utilisation related to home oxygen status. Arch Dis Child Fetal Neonatal Ed. 2006;91(5):F337-F341. DOI: 10.1136/adc.2005.088823

61. Doyle LW, Faber B, Callanan C, et al. Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. Pediatrics. 2006;118(1):108-113. DOI: 10.1542/peds.2005-2522

62. American Academy of Pediatrics Committee on Fetus and Newborn. Hospital discharge of the high-risk neonate. Pediatrics. 2008;122(5):1119-1126. DOI: 10.1542/peds.2008-2174

63. Moore T, Hennessy EM, Myles J, et al. Neurological and developmental outcome in extremely preterm children born in England in 1995 and 2006: the EPICure studies. BMJ. 2012;345:e7961. DOI: 10.1136/bmj.e7961

64. Duke T. Neonatal pneumonia in developing countries. Arch Dis Child Fetal Neonatal Ed. 2005;90(3):F211-F219. DOI: 10.1136/adc.2003.048108

65. Kawaza K, Machen HE, Brown J, et al. Efficacy of a low-cost bubble CPAP system in treatment of respiratory distress in a neonatal ward in Malawi. PLoS One. 2014;9(1):e86327. DOI: 10.1371/journal.pone.0086327

66. Chawanpaiboon S, Vogel JP, Moller AB, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health. 2019;7(1):e37-e46. DOI: 10.1016/S2214-109X(18)30451-0

67. Partridge EA, Davey MG, Hornick MA, et al. An extra-uterine system to physiologically support the extreme premature lamb. Nat Commun. 2017;8:15112. DOI: 10.1038/ncomms15112

---

Document Metadata

---

END OF DOCUMENT